Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)...

por Home, Philip D., Bergenstal, Richard M., Bolli, Geremia B., Ziemen, Monika, Rojeski, Maria, Espinasse, Melanie, Riddle, Matthew C.
Publicado 2017

MON-378 Efficacy and Safety of Romosozumab vs Alendronate Is Similar Across Different Levels of Renal Function Among Postmenopausal Women with Osteoporosis

por Miller, Paul, Cheung, Angela M, Reid, Ian, Rojeski, Maria, Vanderkelen, Mark, Yang, Wenjing, Santiago, Norma Ruiz, Oates, Mary
Publicado 2020

OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis

por Feldman, Robert, Geusens, Piet, Oates, Mary, Thomas, Thierry, Makras, Polyzois, Jakob, Franz, Langdahl, Bente, Yang, Wenjing, Rojeski, Maria, Libanati, Cesar
Publicado 2020

T‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial

por Cosman, Felicia, Lewiecki, E Michael, Ebeling, Peter R, Hesse, Eric, Napoli, Nicola, Matsumoto, Toshio, Crittenden, Daria B, Rojeski, Maria, Yang, Wenjing, Libanati, Cesar, Ferrari, Serge
Publicado 2020

Romosozumab and antiresorptive treatment: the importance of treatment sequence

por Cosman, Felicia, Kendler, David L., Langdahl, Bente L., Leder, Benjamin Z., Lewiecki, E. Michael, Miyauchi, Akimitsu, Rojeski, Maria, McDermott, Michele, Oates, Mary K., Milmont, Cassandra E., Libanati, Cesar, Ferrari, Serge
Publicado 2022

Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density

por Poole, Kenneth ES, Treece, Graham M, Pearson, Rose A, Gee, Andrew H, Bolognese, Michael A, Brown, Jacques P, Goemaere, Stefan, Grauer, Andreas, Hanley, David A, Mautalen, Carlos, Recknor, Chris, Yang, Yu‐Ching, Rojeski, Maria, Libanati, Cesar, Whitmarsh, Tristan
Publicado 2021